Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel
avelumab alone
JAVELIN Lung 200 (all population), 2018
  NCT02395172
RCTmNSCLC - L2 - all populationavelumabdocetaxelpatients with stage IIIB, IV, or recurrent NSCLC with disease progression after previous platinum doublet treatment396 / 396some concern
inconclusive
    no statistically significant result